IN stock · Healthcare sector · Drug Manufacturers—Specialty & Generic
Company Logo

Dr. Reddy's Laboratories Limited

RDYNYSE

52.75

USD
-1.29
(-2.39%)
Market Closed
24.09P/E
17Forward P/E
1.33P/E to S&P500
8.775BMarket CAP
55.51%Div Yield
Upcoming Earnings
- -
Shares Short
9/15/22
1.69M
Short % of Float
- -
Short % of Shares Outs.
1.02%
% Held by Insiders
- -
% Held by Institutions
9.89%
Beta
0.25
PEG Ratio
0.66
52w. high/low
66.16/47.88
Avg. Daily Volume
0.22M
Return %
Stock
S&P 500
1 year
(19.86)
(15.03)
3 years
42.38
27.03
5 years
45.72
47.04
Scale: |
High
Low
18.70
13.85
18.66
7.45
26.54
7.27
41.80
23.13
39.37
28.75
35.16
27.28
41.42
31.32
59.02
38.23
68.00
43.41
54.73
40.67
46.95
29.83
39.96
28.13
42.82
34.67
73.50
33.33
75.50
57.54
65.36
47.88
Currency:
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
Revenue per share
411.53
297.52
412.48
416.56
441.31
570.52
684.83
776.97
869.75
906.81
849.57
856.43
927.28
1,053.23
1,144.04
1,292.46
1,310.83
Earnings per share
58.96
27.83
(30.70)
6.33
65.23
84.11
98.82
126.48
130.17
117.30
72.64
59.13
113.28
117.62
103.95
142.08
179.32
FCF per share
44.68
(3.85)
(1.52)
53.01
(21.25)
44.62
35.23
51.94
56.97
154.58
(117.48)
42.13
127.85
143.12
139.55
54.61
83.28
Dividends per share
2.77
4.39
4.38
7.31
18.10
13.07
15.99
17.55
21.05
24.07
20.45
24.07
24.12
23.62
25.01
24.99
25.00
CAPEX per share
29.94
40.28
28.28
25.39
68.57
50.63
43.21
62.47
89.96
87.19
247.28
66.59
45.15
36.89
75.74
114.84
147.17
Book Value per sh.
262.86
280.03
249.75
254.38
271.72
338.78
430.49
533.78
653.25
752.23
748.42
762.55
844.99
934.92
1,043.58
1,148.59
1,152.67
Comm.Shares outs.
159
168
168
169
169
170
170
170
170
171
166
166
166
166
166
166
166
Avg. annual P/E ratio
0.3
0.5
(0.5)
4.8
0.5
0.4
0.4
0.4
0.4
0.4
0.5
0.6
0.3
0.5
0.6
0.4
24.1
P/E to S&P500
0.0
0.0
(0.0)
0.2
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
1.3
Avg. annual div. yield
17.1%
33.0%
28.7%
24.1%
53.2%
40.9%
43.7%
37.7%
37.4%
52.2%
52.2%
71.3%
62.7%
43.1%
38.2%
46.0%
45.4%
Revenue (m)
65,249
50,006
69,441
70,277
74,693
96,737
116,266
132,170
148,189
154,708
140,809
142,028
153,851
174,600
189,722
214,391
217,351
Operating margin
17.2%
6.7%
(4.1)%
2.9%
16.9%
18.9%
18.2%
19.7%
17.7%
19.1%
9.6%
8.4%
13.6%
9.2%
12.8%
13.7%
16.1%
Depreciation (m)
3,017
6,205
3,814
4,160
4,148
5,213
5,549
7,106
8,100
10,250
11,277
11,710
12,190
12,472
12,796
11,824
11,969
Net profit (m)
9,349
4,678
(5,168)
1,068
11,040
14,262
16,777
21,515
22,179
20,013
12,039
9,806
18,795
19,498
17,238
23,568
29,736
Income tax rate
11.2%
(35.8)%
(29.3)%
48.0%
11.3%
22.8%
22.6%
19.1%
21.2%
26.3%
17.8%
31.6%
16.3%
(8.1)%
34.7%
27.0%
33.2%
Net profit margin
14.3%
9.4%
(7.4)%
1.5%
14.8%
14.7%
14.4%
16.3%
15.0%
12.9%
8.5%
6.9%
12.2%
11.2%
9.1%
11.0%
13.7%
Working capital (m)
18,978
15,228
12,457
13,041
6,578
26,492
32,068
49,684
55,843
55,042
15,375
39,953
54,801
57,556
64,858
83,264
- -
Long-term debt (m)
17,913
12,864
10,132
5,385
5,316
16,335
12,625
20,740
14,307
10,685
5,449
25,089
22,000
1,304
6,299
5,746
- -
Equity (m)
41,677
47,067
42,045
42,915
45,990
57,444
73,085
90,801
111,302
128,336
124,044
126,460
140,197
154,988
173,062
190,527
200,039
ROIC
13.8%
7.1%
(5.3)%
2.5%
21.0%
19.8%
19.8%
19.4%
17.6%
14.4%
9.3%
6.6%
11.8%
12.9%
9.8%
12.6%
Infinity%
Return on capital
12.2%
4.0%
(2.8)%
3.0%
13.5%
16.3%
15.9%
16.4%
15.0%
13.5%
7.0%
6.7%
10.4%
8.2%
10.3%
11.6%
Infinity%
Return on equity
22.4%
9.9%
(12.3)%
2.5%
24.0%
24.8%
23.0%
23.7%
19.9%
15.6%
9.7%
7.8%
13.4%
12.6%
10.0%
12.4%
14.9%
Plowback ratio
95.3%
84.2%
114.3%
(15.4)%
72.3%
84.5%
83.8%
86.1%
83.8%
79.5%
71.8%
59.3%
78.7%
79.9%
75.9%
82.4%
86.1%
Div.&Repurch./FCF
(135.7)%
(111.6)%
- -
13.6%
(84.3)%
29.2%
45.4%
33.8%
34.8%
15.6%
(98.0)%
57.1%
21.4%
18.5%
21.9%
42.1%
28.4%
Forex (INR/USD)
- -
- -
- -
- -
- -
- -
- -
- -
0.016
0.015
0.015
0.015
0.014
0.013
0.014
0.013
0.013
Capital Structure
30 Jun · 2022 | Q1
All numbers in millions
Total liabilities
$ - -
Total assets
$ - -
Long-term debt
$ - -
Cash and equiv.
$ - -
Goodwill
$ - -
Retained earnings
$ - -
Common stock
166
Enterprise Value
$ 8,775
Working Capital
Currency: USD, in millions
2020
2021
2022
Cash & Investments
25,740
34,573
44,365
Receivables
61,754
61,683
70,049
Inventory
35,066
45,412
50,884
Other
7,810
19,357
28,607
Current assets
130,370
148,249
181,106
Acc. Payable
10,745
12,696
25,572
Debt due
20,798
24,009
28,099
Other
41,271
46,686
44,171
Current liabilities
72,814
83,391
97,842
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
13.00%
10.87%
7.28%
Cash flow
(60.85)%
38.05%
7.97%
Earnings
36.72%
30.13%
9.30%
Dividends
(0.02)%
0.99%
5.44%
Book value
10.09%
10.79%
11.54%
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2021
44,175
48,967
49,296
47,284
189,722
2022
49,194
57,632
53,197
54,368
214,391
2023
52,154
- -
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2021
34.93
45.97
1.19
21.85
103.95
2022
34.41
59.80
42.59
5.27
142.08
2023
71.66
- -
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2021
- -
25.01
- -
- -
25.01
2022
- -
24.99
- -
- -
24.99
2023
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Drug Manufacturers—Specialty & Generic
CEO:
Mr. Erez Israeli
Full-time employees:
24,795
City:
Hyderabad
Address:
8-2-337, Road No. 3
IPO:
Nov 8, 2006
Website:
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.